Introduction
============

Pancreatic cancer (PC) causes 33 700 deaths/year in USA, making it the fourth most common cause of cancer deaths; furthermore, the mortality rate for PC has remained unchanged over the past few decades ([@bib1]). Understanding the etiology and identifying the risk factors are essential for the primary prevention of this deadly disease.

Cigarette smoking, a major source of carcinogen exposure, is the only environmental risk factor for PC that has been consistently implicated in epidemiological studies ([@bib2]). Cigarette smoke contains many toxic constituents, including 43 known carcinogens ([@bib3]). Carcinogenic aromatic amines (AAs) and tobacco-specific nitrosamines detected in cigarette smoke are hypothesized to be major causal factors in the etiology of various cancers ([@bib4]). Previous studies by our group ([@bib5],[@bib6]) and a study by other investigators ([@bib7]) showed that individual variations in carcinogen-metabolizing genes modify the risk of smoking-related PC.

Another suspected risk factor for PC is diet ([@bib8]). Epidemiological studies have shown an association between increased risk for PC and high consumption of salt, smoked meat, dehydrated food, fried food and refined sugar ([@bib9]--[@bib11]). In particular, meat cooked at high temperatures, such as barbecued or deep-fried meat, is a source of carcinogenic heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs) ([@bib12],[@bib13]). Processed or smoked meat could also serve as a source of N-nitroso compounds (NOCs), represented by nitrosamines, a suspected class of pancreatic carcinogens ([@bib14]). Notably, the high frequency of K-ras mutation in human PCs parallels that found in pancreatic tumors in hamsters induced by NOCs ([@bib15]). However, investigations pursuing estimates of dietary NOC intakes were impeded by the lack of a good study instrument. The major subclass of HCAs found in the human diet comprises the aminoimidazoazaarenes 2-amino-3-methylimidazo\[4,5-*f*\]quinoline, 2-amino-3,4-dimethylimidazo\[4,5-*f*\]quinoline, 2-amino-3,8-dimethylimidazo\[4,5-*f*\]quinoxaline (MeIQx), 2-amino-3,4,8-trimethylimidazo\[4,5-*f*\]quinoxaline (DiMeIQx) and 2-amino-1-methyl-6-phenylimidazo\[4,5-*b*\]pyridine (PhIP) ([@bib16],[@bib17]). The pancreas is highly susceptible to HCA-induced DNA damage, and studies have shown that HCA compounds induce pancreatic tumors and promote tumor growth in animals ([@bib18],[@bib19]). Furthermore, benzo\[*a*\]pyrene (BaP) is one of the most potent PAH animal carcinogens ([@bib20]), and dietary exposure to it causes increased tumor formation at several sites, particularly in the gastrointestinal tract, in animal models ([@bib21]). Using a well-established meat preparation questionnaire and a relevant database, dietary intake of HCAs and PAHs has been associated with increased risk of PC ([@bib22],[@bib23]). Therefore, the current study examined exposures only to dietary HCAs and PAHs.

Genetic factors that influence individual susceptibility to dietary mutagen exposure-associated PC are unclear. Cytochrome P450 (CYP) 1A2, *N*-acetyltransferase (NAT) and sulfotransferase (SULT) are enzymes involved in the detoxification as well as bioactivation of AAs, HCAs and NOCs ([@bib24]--[@bib27]). Usually, these carcinogens are activated by N-hydroxylation catalyzed by hepatic CYP ([@bib28]). Alternatively, they are either N-acetylated or N-sulfated by NAT or SULT, respectively, for detoxification. However, following N-hydroxylation, they can be O-acetylated or O-sulfated by the same enzymes, yielding highly reactive intermediates capable of binding to DNA ([@bib29]).

More than 40 single-nucleotide polymorphisms (SNPs) of the *CYP1A2* gene have been identified. Because many of the SNPs are in linkage disequilibrium, *CYP1A2\*1D* and *CYP1A2\*1F* have been suggested to be the most informative alleles for *CYP1A2* genotype assessment ([@bib30]). We have demonstrated previously that presence of the *CYP1A2\*1F* allele has additive effects on increased risk of PC among smoking women ([@bib5]). Two NAT isoenzymes---NAT1 and NAT2---are found in humans. The former is expressed in all human tissues, including the pancreas ([@bib31]), whereas the latter is expressed primarily in liver and gastrointestinal tract ([@bib32],[@bib33]). Both NAT1 and NAT2 catalyze the O-acetylation of a number of carcinogenic N-hydroxy AAs and HCAs ([@bib34]). The *NAT1* and *NAT2* genes are located on chromosomes 8p23.1-p21.3 and 8p22, respectively, and both are encoded by single open reading frames of 870 bp that exhibit genetic polymorphisms in human populations ([@bib35]). Molecular epidemiological studies demonstrated that individuals with *NAT1* rapid acetylator genotypes or *NAT2* slow acetylator genotypes and exposed to known AA and HCA carcinogens, such as in cigarette smoke, diet or occupation, were at increased risk for various types of human cancers ([@bib36],[@bib37]). In our previous studies, *NAT1* rapid acetylator genotype and *NAT2* slow acetylator genotype were associated with a significantly increased risk of PC among heavy smokers ([@bib5],[@bib6]).

*SULT1A1* belongs to a gene superfamily involved in the sulfonation of hormones, neurotransmitters, drugs and xenobiotic compounds. O-sulfation is a common step in phase II enzyme detoxification; however, sulfate anions may be cleaved off heterolytically and release electrophils that may bind to DNA ([@bib38]). Also, studies showed that G638A leading to an amino acid change from arginine to histidine at codon 213 (Arg213His) was associated with reduced enzyme activity and thermostability ([@bib39],[@bib40]). A number of studies of *SULT1A1* polymorphisms and cancers of the lung, colon, prostate, bladder, esophagus and urinary tract have had conflicting results ([@bib41]--[@bib46]).

To identify genetic factors involved in carcinogen exposure-associated PC, we examined SNPs of the *CYP1A2*, *NAT* and *SULT* genes in association with AA and HCA exposures in a hospital-based PC case--control study.

Materials and methods
=====================

Study population
----------------

The study population and design were described in detail previously ([@bib23]). Cases were patients with pathologically confirmed primary pancreatic ductal adenocarcinoma and were recruited consecutively from the Gastrointestinal Center at The University of Texas MD Anderson Cancer Center from 2000 to 2006. No restrictions on the recruitment of patients with respect to age, race or sex were used. Also, healthy controls were recruited from among the spouses, friends and non-blood relatives of patients with various types of cancers other than gastrointestinal cancers or other smoking-related cancers. Eligible controls were identified using a brief screening questionnaire to collect information on demographics, cancer history, state of residence, relationship to the respective patient and willingness to participate in a research project. The controls were frequency matched with the cases by age at enrollment (5-year interval), sex and race. All study participants were residents of USA and were able to communicate in English. Written informed consent for interviews and a blood sample were obtained from each participant. The study was approved by the MD Anderson Cancer Center Institutional Review Board.

Data collection
---------------

A trained study coordinator administered a structured risk factor questionnaire to collect demographic data and information on cigarette smoking, alcohol consumption, occupational history, medical history and family history of cancer. Both patients and controls were interviewed by the same study personnel. No proxy interviews were conducted. Cumulative smoking was calculated in pack-years, i.e. the number of packs smoked per day multiplied by the number of years of smoking. Those who had smoked for \>20 pack-years were considered to be heavy smokers. The individuals who consumed \>60 g/day alcohol were defined as heavy drinkers. Information on dietary mutagen exposure was collected in personal interviews using a meat preparation questionnaire ([@bib23]). The questionnaire provided information on daily consumption of MeIQx, PhIP, DiMeIQx and BaP as well as a mutagenic index (revertant colonies per grams of daily meat intake), which was calculated using previously obtained laboratory information regarding the mutagenic activity of meat sample extracts in a standard Ames assay with *Salmonella typhimurium* strain TA98 ([@bib47]).

DNA extraction and genotyping assays
------------------------------------

Blood samples were collected in heparinized vacutainers (BD Biosciences, Franklin Lakes, NJ). Peripheral blood mononuclear cells were separated from freshly drawn blood using Ficoll-Hypaque density gradient centrifugation (Amersham Pharmacia Biotech, Piscataway, NJ). DNA was extracted from mononuclear cells using a FlexiGene DNA kit (Qiagen, Valencia, CA) and the Maxwell 16 automated system (Promega, Madison, WI).

*CYP1A2\*1F* polymorphism (rs762551) was determined by polymerase chain reaction (PCR)--restriction fragment length polymorphism ([@bib5]) and Taqman ([@bib48]) methods as described previously. Probes and oligonucleotides were obtained from Applied Biosystems (Foster City, CA) using the Assay-by-Design product. The PCR amplification was done using the ABI Prism 7900 HT sequence detector.

Genotyping of *SULT1A1* for polymorphisms at G638A was performed by PCR--restriction fragment length polymorphism method. The primers used for amplification of the target fragment were SULT F 5′-GGGTTTCTAGGAGAAGTGGC-3′ and SULT R 5′-GAGATGCTGTGGTCCATGA-3′, which produce a 275 bp exon 7 region of the *SULT1A1* gene containing the G638A site. PCR was performed in a 20 μl reaction mixture containing 100 ng DNA, 0.25 μM each primer, 50 μM each deoxy nucleotide triphosphate (dNTP) and 0.4 U *Taq* DNA polymerase with 1.5 mM MgCl~2~ containing 10× ammonium reaction buffer (Gene Choice, Frederick, MD). The reaction was carried out under the following conditions: an initial melting step for 6 min at 94°C followed by 32 cycles for 45 s at 94°C, 35 s at 62°C and 30 s at 72°C and a final elongation for 7 min at 72°C. The PCR products were then digested using the restriction enzyme HhaI (New England Biolabs, Beverly, MA) overnight and separated on a 2.5% agarose gel. The wild-type G allele had an HhaI restriction site that resulted in two bands (155 and 115 bp, respectively); the A allele lacked an HhaI restriction site and thus produced a single 270 bp fragment. The laboratory personnel were blinded to the case--control status of the samples.

Eight SNPs of the *NAT1* gene (C97T, C190T, G445A, C559T, G560A, A752T, T1088A and C1095T) and seven SNPs of the *NAT2* gene (G191A, C282T, T341C, C481T, G590A, A803G and G857A) were analyzed using Taqman as described previously ([@bib49],[@bib50]). About 10% of the samples were analyzed in duplicate, and inconsistent results from five samples were excluded from the final risk analysis. The *NAT1\*10* allele or *NAT2* slow acetylation alleles (*NAT2\*5*, *\*6*, *\*7* and *\*14* clusters) were considered to be the 'at-risk' alleles.

Statistical analysis
--------------------

Chi-square tests were used to compare the distribution of categorical variables and genotype frequencies in the patients and controls. Unconditional multivariate logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). The basic statistical models were adjusted for sex, race (white, Hispanic, black and Asian), age (≤50, 51--60, 61--70 and \>70 years), smoking status (non-smoker, ≤20 pack-years and \>20 pack-years), alcohol consumption (never, ≤60 g/day and \>60 g/day), history of diabetes (yes or no) and family history of cancer among first-degree relatives (yes or no) when appropriate. Dietary mutagen intake variables were dichotomized using the 60th percentile of the control value as the cutoff as reported previously ([@bib23]). Genotype-related evaluations were restricted to non-Hispanic white participants because of a small number of minority participants. To explore the potential gene--environment interaction according to smoking status (never smoker versus ever smoker), number of pack-years (0, ≤20 and \>20) and dietary intake of HCAs (≤60th or \>60th percentile of the control value), the cross-product term for genotype and the variable of interest was generated in unconditional logistic regression models. A two-by-four table was constructed to evaluate the scale of interaction (i.e. the departure from an additive or multiplicative model). The significance of the interaction term was determined using a likelihood ratio test, with the full model containing the interaction term, the main effect of genotype, the exposure variable and the reduced model lacking the interaction term. OR trends were examined using the score test with adjustment for other risk factors, treating the interaction term as a continuous variable.

To explore the possible interactions of the many environmental and genetic factors involved in this study, we used logic regression ([@bib51]) to find the best logical combination of factors that predicted case--control status. The method works by searching all possible combinations of factors joined by 'and/or' operators and finding the one that yielded the best separation between cases and controls. The method results in a new composite predictor 'L' that is a single dichotomous factor in a logistic regression. We then ran a permutation test (1000 permutations) to obtain a *P* value for this composite factor that takes the multiple testing aspect of logic regression into account. Factors that were considered in the analysis included smoking, dietary mutagen exposure, family history of cancer among first-degree relatives, diabetes, alcohol and genotype. Pack-years were selected as the reflection of smoking status. Non-smoker, light smoker and heavy smoker were coded as 0, 1 and 2, respectively. We considered two different cut-points for defining light smokers and heavy smokers: 20 or 40 pack-years. For dietary mutagen exposure, the influence of individual mutagen intake (MeIQx, DiMeIQx, PhIP and BaP) and overall mutagenicity (revertants per gram per day) was considered separately. We used the median or the third quartile in controls as potential group cut-point for each of those variables. Alcohol consumption was considered by groups of non-drinker, light drinker and heavy drinker, using \>60 ml ethanol/day as the cutoff for heavy drinkers. For the genetic variables, both dominant and recessive models for each genetic marker were considered.

All statistical analyses were performed using the Stata 9.0 (StataCorp, College Station, TX), R and SAS software programs. All tests were two sided and *P* values \<0.05 were indicative of statistical significance.

Results
=======

Characteristics of the study subjects and genotype frequency
------------------------------------------------------------

We performed this study in 755 patients with pancreatic adenocarcinoma and 636 healthy frequency-matched controls; their demographics and potential risk factors for PC and genotype frequency are listed in [Table I](#tbl1){ref-type="table"}. We observed no significant differences between the patients and controls according to age, sex or alcohol consumption, but we did according to race, family history of cancer, history of diabetes and smoking status. The mean ages of the patients and controls (±standard deviation) were 62.1 ± 10.2 years and 60.9 ± 10.1 years, respectively (*P* = 0.89). Although the number was small, there were fewer minority controls than minority patients (8 versus 14%) because of the known challenges in minority recruitment. All genotype distributions in controls followed the Hardy--Weinberg equilibrium among non-Hispanic white participants. We observed no significant differences between patients and controls in the distribution of these genotypes.

###### 

Distribution of selected variables among cases and controls

  Variable                                                    Cases (*N* = 755)   Controls (*N* = 636)   *P* value
  ----------------------------------------------------------- ------------------- ---------------------- -----------
  Age at recruitment (years)                                                                             0.26
      ≤50                                                     103 (13.7)          103 (16.2)             
      51--60                                                  221 (29.3)          194 (30.5)             
      61--70                                                  260 (34.4)          219 (34.4)             
      \>70                                                    171 (22.6)          120 (18.9)             
  Gender                                                                                                 0.33
      Female                                                  320 (42.4)          253 (39.8)             
      Male                                                    435 (57.6)          383 (60.2)             
  Race                                                                                                   0.004
      Non-Hispanic white                                      649 (86.0)          585 (92.0)             
      Hispanic                                                47 (6.2)            24 (3.8)               
      Black                                                   50 (6.6)            21 (3.2)               
      Other                                                   9 (1.2)             6 (1.0)                
  Family history of cancer[a](#tblfn1){ref-type="table-fn"}                                              \<0.001
      No                                                      175 (23.3)          197 (31.0)             
      Yes                                                     577 (76.7)          438 (69.0)             
  History of diabetes[b](#tblfn2){ref-type="table-fn"}                                                   \<0.001
      No                                                      567 (75.1)          571 (90.0)             
      Yes                                                     188 (24.9)          64 (10.0)              
  Smoking status                                                                                         \<0.001
      Non-smokers                                             304 (40.3)          310 (48.7)             
      ≤20 pack-years                                          186 (24.6)          166 (26.1)             
      \>20 pack-years                                         265 (35.1)          160 (25.2)             
  Alcohol consumption[c](#tblfn3){ref-type="table-fn"}                                                   0.345
      Never                                                   334 (44.2)          271 (43.6)             
      ≤60 g/day                                               362 (47.9)          313 (50.4)             
      \>60 g/day                                              59 (7.9)            37 (6.0)               
  *CYP1A2\*1F*[d](#tblfn4){ref-type="table-fn"}                                                          0.957
      AA                                                      341 (52.5)          307 (52.5)             
      AC                                                      276 (42.5)          247 (42.2)             
      CC                                                      32 (4.9)            31 (5.3)               
  *Sult1A1*                                                                                              0.651
      GG                                                      248 (38.2)          228 (39.0)             
      GA                                                      368 (56.7)          321 (54.9)             
      AA                                                      33 (5.1)            36 (6.2)               
  *NAT1*                                                                                                 0.353
      Non\*10                                                 431 (66.4)          403 (68.9)             
      \*10                                                    218 (33.6)          182 (31.1)             
  *NAT2*                                                                                                 0.797
      Rapid                                                   38 (5.9)            34 (5.8)               
      Intermediate                                            248 (38.2)          213 (36.4)             
      Slow                                                    363 (55.9)          338 (57.8)             

Information was missing for three cases and one control because of adopted family.

Information was missing for one control.

Information was missing for 15 controls.

Distribution for non-Hispanic white.

Interaction of genotypes with smoking
-------------------------------------

Next, we examined the association between these genotypes and the risk of PC in relation to cigarette smoking in the non-Hispanic white patients and controls. We confirmed our previously reported observations that a significant trend of increased risk of PC was associated with smoking and *CYP1A2* and *NAT* genotypes in women but not in men ([Table II](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Heavy smokers among women (\>20 pack-years) carrying the *CYP1A2\*1F* AA genotype had an adjusted OR of 4.36 (95% CI = 2.15--8.84) compared with never smokers carrying the AC or CC genotypes. Also, heavily smoking women with the *NAT1\*10* allele had a 4-fold higher risk (OR, 4.01; 95% CI = 1.73--9.29) of PC when compared with never smokers who did not carry the *NAT1\*10* allele. In addition, all the gene--smoking interactions were statistically significant at the multiplicative scale among women.

###### 

Interaction of genotypes with cigarette smoking in non-Hispanic white participants

  Genotype         Smoke (pack-years)   Male     Female                                                  
  ---------------- -------------------- -------- ------------------- ------- ------- ------------------- ---------
  *CYP1A2\*1F*                                                       0.805                               \<0.001
      AC/CC        Never                60/62    1.0                         55/79   1.0                 
      AA           Never                78/86    0.99 (0.61--1.60)           60/62   1.35 (0.80--2.25)   
      AC/CC        ≤20                  50/43    1.11 (0.64--1.94)           31/27   1.51 (0.78--2.91)   
      AA           ≤20                  42/47    0.94 (0.53--1.64)           35/24   2.31 (1.21--4.42)   
      AC/CC        \>20                 74/44    1.75 (1.03--2.97)           38/22   2.24 (1.15--4.38)   
      AA           \>20                 81/72    1.06 (0.64--1.73)           45/16   4.36 (2.15--8.84)   
      *P*~trend~                                 0.430                               \<0.001             
  *SULT1A1*                                                          0.023                               \<0.001
      GG           Never                59/52    1.0                         43/53   1.0                 
      GA/AA        Never                79/96    0.76 (0.47--1.25)           72/89   0.97 (0.57--1.65)   
      GG           ≤20                  27/33    0.73 (0.38--1.41)           19/21   1.00 (0.46--2.19)   
      GA/AA        ≤20                  60/53    0.94 (0.54--1.62)           43/30   1.91 (1.00--3.62)   
      GG           \>20                 49/48    0.84 (0.48--1.47)           38/19   2.45 (1.18--5.08)   
      GA/AA        \>20                 97/69    1.21 (0.72--2.01)           44/18   2.96 (1.45--6.06)   
      *P*~trend~                                 0.330                               \<0.001             
  *NAT1*                                                             0.408                               0.012
      Non\*10      Never                88/101   1.0                         70/96   1.0                 
      \*10         Never                50/47    1.22 (0.74--2.02)           45/46   1.34 (0.78--2.29)   
      Non\*10      ≤20                  62/56    1.18 (0.73--1.89)           45/38   1.64 (0.93--2.87)   
      \*10         ≤20                  25/30    0.92 (0.49--1.73)           17/13   1.98 (0.89--4.44)   
      Non\*10      \>20                 97/82    1.24 (0.81--1.90)           55/27   2.71 (1.50--4.89)   
      \*10         \>20                 49/35    1.55 (0.91--2.66)           27/10   4.01 (1.73--9.29)   
      *P*~trend~                                 0.300                               \<0.001             
  *NAT2*                                                             0.021                               0.002
      R/I          Never                62/53    1.0                         56/65   1.0                 
      Slow         Never                76/95    0.65 (0.40--1.06)           59/77   0.81 (0.48--1.36)   
      R/I          ≤20                  39/38    0.80 (0.44--1.45)           23/21   1.47 (0.72--3.03)   
      Slow         ≤20                  48/48    0.77 (0.44--1.37)           39/30   1.34 (0.71--2.53)   
      R/I          \>20                 58/51    0.87 (0.51--1.51)           39/16   2.71 (1.30--5.65)   
      Slow         \>20                 88/66    1.03 (0.62--1.71)           43/21   2.27 (1.16--4.46)   
      *P*~trend~                                 0.622                               0.001               

R/I = rapid/intermediate.

OR was adjusted for age, family history of cancer, history of diabetes and alcohol consumption.

![Interactive effects of *NAT1* genotype with cigarette smoking (left panel) or dietary BaP intake (right panel) on risk of PC. NS, never smokers; LS, light smokers (≤20 pack-years); HS, heavy smokers (\>20 pack-years); high, \>52.10 ng/day (60th percentile of controls) of BaP intake; low, ≤52.10 ng/day. Solid bars, *NAT1* non\*10; open bars, NAT1\*10.](carcinbgn085f01_ht){#fig1}

Genotype and dietary mutagen exposure
-------------------------------------

The mean intake of dietary mutagens (MeIQx, DiMeIQx, PhIP and BaP) and mutagenicity index in consumed meat were higher in patients than in controls as we reported previously ([@bib23]). When we dichotomized dietary mutagen intake according to the 60th percentile of control values, PhIP and BaP intake was associated with a 1.37-fold (95% CI = 0.99--1.91) and 1.64-fold (95% CI = 1.19--2.26) increased risk of PC, respectively, in men but not women (data not shown). Consequently, we examined the joint effect of dietary mutagen intake and genotype in male non-Hispanic white participants only ([Table III](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Of the four genes investigated, *NAT1\*10* showed significant interaction with each of the five parameters of mutagen exposure in modifying the risk of PC. Individuals carrying the *NAT1\*10* allele and having a higher intake of (in the top 40%) dietary mutagens had a 1.64- to 2.54-fold higher risk of PC than did those without the *NAT1\*10* allele and had lower levels of dietary mutagen intake. Finally, we did not observe any significant interactions between the *CYP1A2\*1F*, *SULT1A1* and *NAT2* genotypes and dietary mutagen intake in modification of the risk of PC among men and we did not observe a significant interaction between any genotype and dietary mutagen intake in women (data not shown).

###### 

Interaction between genotype and dietary mutagen intake in men

  Mutagen          *CYP1A2\*F*   Cases/controls   OR (95% CI)[a](#tblfn6){ref-type="table-fn"}   *P*~interaction~   *SULT1A1*   Cases/controls   OR (95% CI)[a](#tblfn6){ref-type="table-fn"}   *P*~interaction~
  ---------------- ------------- ---------------- ---------------------------------------------- ------------------ ----------- ---------------- ---------------------------------------------- ------------------
  MeIQx                                                                                                                                                                                         
      ≤44.98       AC/CC         72/67            1.0                                            0.148              GG          51/67            1.0                                            0.566
      ≤44.98       AA            93/100           0.9 (0.6--1.4)                                                    GA/AA       114/100          1.4 (0.9--2.2)                                 
      \>44.98      AC/CC         74/57            1.2 (0.7--1.9)                                                    GG          70/57            1.4 (0.8--2.4)                                 
      \>44.98      AA            74/78            0.8 (0.5--1.3)                                                    GA/AA       78/78            1.2 (0.7--1.9)                                 
  *P*~trend~                                      0.753                                                                                          0.450                                          
  DiMeIQx                                                                                                                                                                                       
      ≤2.37        AC/CC         80/72            1.0                                            0.569              GG          53/69            1.0                                            0.995
      ≤2.37        AA            86/107           0.8 (0.5--1.2)                                                    GA/AA       113/110          1.2 (0.8--1.9)                                 
      \>2.37       AC/CC         66/52            1.1 (0.7--1.8)                                                    GG          68/55            1.4 (0.8--2.3)                                 
      \>2.37       AA            81/71            0.9 (0.6--1.6)                                                    GA/AA       79/68            1.4 (0.8--2.3)                                 
      *P*~trend~                                  0.938                                                                                          0.319                                          
  PhIP                                                                                                                                                                                          
      ≤162.3       AC/CC         70/75            1.0                                            0.133              GG          62/77            1.0                                            0.902
      ≤162.3       AA            88/105           0.9 (0.6--1.4)                                                    GA/AA       96/103           1.1 (0.7--1.7)                                 
      \>162.3      AC/CC         76/49            1.6 (0.9--2.7)                                                    GG          59/47            1.5 (0.9--2.5)                                 
      \>162.3      AA            79/73            1.1 (0.7--1.8)                                                    GA/AA       96/75            1.5 (0.9--2.4)                                 
      *P*~trend~                                  0.436                                                                                          0.071                                          
  BaP                                                                                                                                                                                           
      ≤52.10       AC/CC         67/71            1.0                                            0.440              GG          55/70            1.0                                            0.494
      ≤52.10       AA            77/104           0.8 (0.5--1.2)                                                    GA/AA       89/105           1.0 (0.6--1.6)                                 
      \>52.10      AC/CC         79/53            1.5 (0.9--2.4)                                                    GG          66/54            1.4 (0.9--2.4)                                 
      \>52.10      AA            90/74            1.2 (0.8--2.0)                                                    GA/AA       103/73           1.7 (1.0--2.7)                                 
      *P*~trend~                                  0.197                                                                                          0.016                                          
  Mutagenicity                                                                                                                                                                                  
      ≤7141        AC/CC         70/71            1.0                                            0.169              GG          53/69            1.0                                            0.917
      ≤7141        AA            86/99            0.9 (0.6--1.4)                                                    GA/AA       103/101          1.2 (0.8--1.9)                                 
      \>7141       AC/CC         76/53            1.3 (0.8--2.2)                                                    GG          68/55            1.4 (0.8--2.4)                                 
      \>7141       AA            81/79            0.9 (0.6--1.5)                                                    GA/AA       89/77            1.3 (0.8--2.2)                                 
      *P*~trend~                                  0.685                                                                                          0.132                                          
                                                                                                                                                                                                
  MeIQx            *NAT1*                                                                                           *NAT2*                                                                      
      ≤44.98       Non\*10       115/115          1.0                                            0.005              R/I         64/68            Reference                                      0.355
      ≤44.98       Any\*10       50/52            1.0 (0.6--1.6)                                                    S           101/99           1.1 (0.7--1.7)                                 
      \>44.98      Non\*10       83/96            0.8 (0.5--1.2)                                                    R/I         66/54            1.3 (0.7--2.1)                                 
      \>44.98      Any\*10       65/39            1.6 (1.0--2.7)                                                    S           82/81            0.9 (0.6--1.6)                                 
      *P*~trend~                                  0.210                                                                                          0.922                                          
  DiMeIQx                                                                                                                                                                                       
      ≤2.37        Non\*10       118/127          1.0                                            0.012              R/I         64/68            1.0                                            0.799
      ≤2.37        Any\*10       48/52            1.0 (0.6--1.7)                                                    S           102/111          0.9 (0.6--1.5)                                 
      \>2.37       Non\*10       80/84            0.9 (0.6--1.4)                                                    R/I         66/54            1.2 (0.7--2.1)                                 
      \>2.37       Any\*10       67/39            1.8 (1.1--3.0)                                                    S           81/69            1.1 (0.7--1.9)                                 
      *P*~trend~                                  0.142                                                                                          0.885                                          
  PhIP                                                                                                                                                                                          
      ≤162.3       Non\*10       105/123          1.0                                            0.011              R/I         62/66            1.0                                            0.858
      ≤162.3       Any\*10       53/57            1.1 (0.7--1.7)                                                    S           96/114           0.9 (0.6--1.4)                                 
      \>162.3      Non\*10       93/88            1.1 (0.7--1.7)                                                    R/I         68/56            1.3 (0.7--2.1)                                 
      \>162.3      Any\*10       62/34            2.2 (1.3--3.7)                                                    S           87/66            1.3 (0.8--2.1)                                 
      *P*~trend~                                  0.018                                                                                          0.293                                          
  BaP                                                                                                                                                                                           
      ≤52.10       Non\*10       98/117           1.0                                            0.004              R/I         57/69            1.0                                            0.592
      ≤52.10       Any\*10       46/58            0.9 (0.6--1.6)                                                    S           87/106           1.0 (0.6--1.6)                                 
      \>52.10      Non\*10       100/94           1.2 (0.8--1.8)                                                    R/I         73/53            1.7 (1.0--2.8)                                 
      \>52.10      Any\*10       69/33            2.5 (1.5--4.3)                                                    S           96/74            1.5 (0.9--2.4)                                 
      *P*~trend~                                  0.003                                                                                          0.114                                          
  Mutagenicity                                                                                                                                                                                  
      ≤7141        Non\*10       105/115          1.0                                            0.005              R/I         59/64            1.0                                            0.592
      ≤7141        Any\*10       51/55            0.9 (0.6--1.6)                                                    S           97/106           1.0 (0.6--1.6)                                 
      \>7141       Non\*10       93/96            0.9 (0.6--1.4)                                                    R/I         71/58            1.3 (0.8--2.2)                                 
      \>7141       Any\*10       64/36            1.9 (1.2--3.2)                                                    S           86/74            1.1 (0.7--1.8)                                 
      *P*~trend~                                  0.045                                                                                          0.510                                          

R/I = rapid/intermediate; S = slow.

OR was adjusted for age, family history of cancer, history of diabetes, smoking status and alcohol consumption.

Fitted logic regression model
-----------------------------

Because our study involves multiple exposure and genetic factors, we explored the gene--gene and gene--environmental interactions using the logic regression approach ([@bib51]). This method searches all possible combinations of factors joined by and/or operators and identifies the best composite predictor *L* that is a single dichotomous factor. The logistic regression model containing the newly created factor *L* is shown in [Table IV](#tbl4){ref-type="table"}. The fitted model indicated that subjects who have \[(history of diabetes = yes and *SULT1A1* = GA/GG) or (*CYP1A2\*1F* = CA/AA and not a light smoker)\] or \[(heavy smoker or *NAT2* = rapid) and (heavy drinker or *NAT1* = any\*10)\] have a significantly increased risk of PC compared with the other group (OR = 2.59, *P* \< 0.001 based on 1000 permutation tests). This predictor indicates three distinct groups that demonstrated a greater probability of being in the PC than control groups: (i) those with diabetes and *SULT1A1* GA/GG genotype; (ii) those who are not light smokers carrying the *CYP1A2\*1F* CA/AA genotype and (iii) those who are heavy smokers or with the *NAT2* rapid genotype and being either heavy drinkers or possess the *NAT1*\*10 allele. The case--control status broken out by these three groups is shown in [Table V](#tbl5){ref-type="table"}.

###### 

Fitted logistic regression model for case--control in non-Hispanic white participants

  Variable   Case, *n* (%)   Control, *n* (%)   OR          *P*
  ---------- --------------- ------------------ ----------- ---------
  *L* = 0    332 (46)        390 (54)           Reference   
  *L* = 1    194 (69)        88 (31)            2.59        \<0.001

*L* = 1: \[(history of diabetes = yes and *SULT1A1* = GA/GG) or (*CYP1A2\*1F* = CA/AA and not a light smoker)\] or \[(heavy smoker or *NAT2* = rapid) and (heavy drinker or *NAT1* = \*10)\]. *L* = 0: except for above. *P* value was calculated based on 1000 permutation tests. The 95th percentile of OR in the permutation distribution was 1.27.

###### 

Case--control status for three components of composite predictor from logic regression analysis

  Variable                                                                        Case, *n* (%)   Control, *n* (%)
  ------------------------------------------------------------------------------- --------------- ------------------
  History of diabetes = yes or *SULT1A1* = GA/GG                                  419 (49)        432 (51)
  History of diabetes = yes and *SULT1A1* = GA/GG                                 107 (69)        46 (31)
  *CYP1A2\*1F* = CA/AA or a light smoker                                          504 (52)        470 (48)
  *CYP1A2\*1F* = CA/AA and not a light smoker                                     22 (73)         8 (27)
  Not \[(heavy smoker or *NAT2* = rapid) and (heavy drinker or *NAT1* = \*10)\]   440 (51)        432 (49)
  \[(Heavy smoker or *NAT2* = rapid) and (heavy drinker or *NAT1* = \*10)\]       86 (65)         46 (35)

Discussion
==========

In this large-scale case--control study, we examined the effect of genetic variations in carcinogen metabolism on the risk of PC associated with cigarette smoking and dietary mutagen intake. We found a significantly increased risk of PC associated with smoking and dietary mutagen intake in women and men, respectively. Furthermore, we observed a significant interaction of the *NAT1* genotype with dietary mutagens in modification of the risk of PC among men. These are the first reported data to demonstrate a sex difference in susceptibility to dietary mutagen intake-related PC and in gene--diet interactions in modification of the risk of PC.

Previous epidemiological studies revealed a higher smoking-related relative risk of PC in women than in men ([@bib52],[@bib53]). Also, Duell *et al.* ([@bib7]) reported a significant interaction between the *GSTT1*-null genotype and heavy smoking in increasing the risk of PC in women but not men. We showed previously, in a smaller sample of the current study population, a stronger association between *CYP1A2*, *NAT1/2* gene polymorphisms and smoking with PC in women than in men ([@bib5]) and these results were reconfirmed in this study. These observations suggest the existence of hormonal or other gender-specific factors that modulate the risk of smoking-related PC. In the present study, we examined the effect of the phase II enzyme SULT1A1, which is also involved in hormone metabolism, on the risk of smoking-related PC. We found that the *SULT1A1* Arg213His polymorphism did not have a significant main effect or interactive effect with smoking on the risk of PC. Thus, determining the mechanism responsible for the sex difference in susceptibility to smoking-related PC requires further investigation.

We have reported previously the association between dietary mutagen intake and PC risk that we observed in the present study population ([@bib23]). Our new findings reported herein are the sex differences in susceptibility to dietary mutagen intake-related PC and the effects of genotype on PC risk modification. For undetermined reasons, we observed a higher PC risk related to dietary PhIP and BaP intake in men than in women, which is directly opposite to the trend in smoking, wherein we observed higher susceptibility to PC from cigarette smoking in women than in men. This observation is consistent with findings from a recent cohort study that total, red or high-temperature cooked meat intake was positively associated with PC in men but not women ([@bib54]). A higher level of exposure to dietary mutagens or higher levels of iron in men or sex differences in susceptibility to such exposures were discussed as explanations to their observations ([@bib54]). When we compared the pack-years of smoking and dietary mutagen intake separately in patients and controls, men consistently had a higher level of exposure than women in all parameters examined (data not shown). Thus, the association between dietary mutagen exposure and risk of PC in men could be related to a higher level of exposure in this group. In contrast, genetic differences in carcinogen metabolism rather than differences in the exposure level between men and women are more likely to be responsible for the sex differences in susceptibilities to smoking because women actually had lower level of exposure than men. However, we did not observe a sex difference in the distribution of the *CYP1A2\*1F*, *NAT1*, *NAT2* and *SULT1A1* genotypes in patients of the current study (data not shown). Based on previously reported evidence regarding hormonal regulation of *NAT* expression in mammalian tissues ([@bib55]), sex differences in dietary mutagen sensitivity may relate to different patterns of expression of the *NAT1* gene in men and women. Other epidemiological studies of meat consumption that have examined sex-specific PC risk have not demonstrated clear sex differences ([@bib9],[@bib56]--[@bib58]). Thus, our observations must be confirmed in other study populations and for other genes involved in dietary mutagen metabolism.

Of the four genes examined in the present study, *NAT1* had the most pronounced effect on the risk of PC in interaction with dietary mutagen intake. This result is understandable because NAT1 is the predominant NAT protein expressed in the human pancreas ([@bib31]). Pancreas is different from any other digestive organs because it does not have direct contact with food carcinogens and all exposures are blood borne. In this case, the carcinogen metabolic capacity in the target tissue may play a more important role than the hepatic metabolism. Since *NAT1\*10* has been shown to confer a rapid acetylator phenotype ([@bib59]), the increased risk of PC associated with this allele may be explained by a larger amount of reactive carcinogens activated by NAT1 in the target tissue. Our results do not support a significant role for the *CYP1A2\*1F*, *SULT1A1* and *NAT2* genotype with dietary mutagen in modifying the risk of PC.

When multiple genetic and environmental factors were considered in a logic regression approach, we observed possible interactions of diabetes with *SULT1A1* genotype and *CYP1A2\*1F* genotype with smoking in modifying the risk of PC. In addition, heavy smoking, heavy drinking and *NAT* genotypes were also identified as significant contributors to the final risk model. In contrast, none of the mutagen exposure parameters were chosen by logic regression as the strongest predictors of PC. The relationship of diabetes and *SULT1A1* genotype has not been reported previously. SULT enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. The *SULT1A1* gene encodes one of the two phenol SULTs with thermostable enzyme activity. We speculate that the reduced enzyme activity conferred by the *SULT1A1* variant alleles may render the pancreatic cells more susceptible to some unknown xenobiotics or hormones since neither smoking nor dietary mutagen exposure showed interaction with this genotype in modifying the risk of PC.

Our study had several limitations. First, it was a hospital-based study conducted in a single tertiary referral cancer center, so the data may not be applicable to the general population. Second, we restricted the genetic analysis to non-Hispanic white participants because of the small number of minorities enrolled in the study. Third, we did not consider information on body mass index or other dietary factors (e.g. intake of calories, fat, fruits and vegetables, etc.). Fourth, the assessment of exposure to dietary mutagen was limited to HCAs and PAHs. Although NOC exposure could modify the risk of PC via modulation of carcinogen metabolic enzymes or synergistic action with other carcinogens, the role of NOC exposure on the risk association was not considered in this study. Last but not least, dietary exposure to HCAs and PAHs was assessed using self-reported data on eating habits 1 year before the cancer diagnosis or control recruitment. This type of assessment did not consider the lifetime exposure durations or fluctuations. As the sample size increases in our ongoing study and a better study instrument is developed, some of these limitations may be overcome.

In this large hospital-based PC case--control study, we found significant interactions of the *CYP1A2\*1F* and *NAT1\*10* genotypes with smoking among women and *NAT1* genotype with dietary mutagen intake among men. We also showed a number of genetic and environmental factors that appear to be strong predictors of PC using a logic regression model. These results suggest mechanisms of pancreatic carcinogenesis but need to be confirmed in other study populations.
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AA

:   aromatic amine

BaP

:   benzo\[*a*\]pyrene

CI

:   confidence interval

CYP

:   cytochrome P450

DiMeIQx

:   2-amino-3,4,8-trimethylimidazo\[4,5-f\]quinoxaline

HCA

:   heterocyclic amine

MeIQx

:   2-amino-3,8-dimethylimidazo\[4,5-f\]quinoxaline

NAT

:   *N*-acetyltransferase

NOC

:   N-nitroso compound

OR

:   odds ratio

PAH

:   polycyclic aromatic hydrocarbon

PC

:   pancreatic cancer

PCR

:   polymerase chain reaction

PhIP

:   2-amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine

SNP

:   single-nucleotide polymorphism

SULT

:   sulfotransferase
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